Aug. 18 at 11:31 AM
$ANIP To get an idea of ANIP's value - ANIP's Q2 net cash flow from operations (on per share basis) was
$3.80 and did very well when compared to other pharma companies:
LLY (PPS
$701.23) was lower than ANIP by 10%
ALNY (PPS
$448.91) was lower than ANIP by 69%
VTRX (PPS
$392.79) beat ANIP by 9%
UTHR (PPS
$313.13) beat ANIP by 5%
ABBV (PPS
$206.69) was lower than ANI by 23%
JNJ (PPS
$176. 64) was lower than ANIP by 58%.
LGND (PPS
$151.08) was lower than ANIP by 78%
ZTS (PPS
$154.11) was lower than ANIP by 88%
ABT (PPS
$131.75) was lower than ANIP by 69%
MRK (PPS
$84.21) was lower than ANIP by 66%.
In addition, ANIP has yet to announce the launch of INZIRQO and TEZRLY, though their 10-Q filing states the following:
"During the second quarter, we commercialized two 505(b)
(2) products acquired from Novitium, Tezruly and Inzirqo. We are innovating in our go-to-market strategy through creative partnerships and a sales force for these products."
